Murchinson Ltd. Invests $4.23 Million in OmniAb, Inc. (NASDAQ:OABI)

Murchinson Ltd. bought a new stake in OmniAb, Inc. (NASDAQ:OABI) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 1,000,000 shares of the company’s stock, valued at approximately $4,230,000. OmniAb comprises about 1.2% of Murchinson Ltd.’s holdings, making the stock its 14th largest position. Murchinson Ltd. owned approximately 0.85% of OmniAb at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Towerview LLC increased its position in OmniAb by 114.0% in the 2nd quarter. Towerview LLC now owns 535,000 shares of the company’s stock valued at $2,006,000 after acquiring an additional 285,000 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of OmniAb by 6.9% in the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares during the period. Rice Hall James & Associates LLC raised its stake in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the last quarter. Isthmus Partners LLC lifted its holdings in shares of OmniAb by 37.2% during the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after purchasing an additional 143,387 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in OmniAb in the 2nd quarter valued at $449,000. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Stock Down 1.8 %

Shares of OmniAb stock opened at $3.91 on Wednesday. The company has a 50-day moving average of $4.07 and a two-hundred day moving average of $4.22. OmniAb, Inc. has a 12-month low of $3.56 and a 12-month high of $6.72.

Analyst Upgrades and Downgrades

OABI has been the topic of a number of recent analyst reports. Benchmark reiterated a “buy” rating and set a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price target on shares of OmniAb in a research note on Friday, August 16th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.